Abstract / Summary
Mirabegron is a beta-3 adrenoceptor agonist for the treatment of overactive bladder syndrome. Our objective was to measure the risk of chorioretinal disease in new users of mirabegron compared to new users of anticholinergics. We conducted an active comparator, retrospective cohort study using routinely collected data in older adults. We defined three exposure groups: newer OAB anticholinergic users (darifenacin, fesoterodine, solifenacin, tolterodine, and trospium, [reference group]), oxybutynin users, and mirabegron users. The primary outcome was use of an intraocular anti-VEGF medication (as a marker of chorioretinal disease). In the primary analysis of the weighted cohort there was an increased hazard for mirabegron users (HR 1.15, 95%CI 1.03-1.27). However, we found that mirabegron users had a similarly elevated risk in the 6 months prior to their exposure to mirabegron (HR 1.15, 95%CI 1.03-1.28), suggesting the observed risk was due to residual confounding. Our results do not suggest that mirabegron use is associated with an elevated risk of chorioretinal disease.